[ad_1]
New VIDA analysis packages & novel biomarkers empower trial sponsors to unlock breakthrough insights
SAN FRANCISCO, May 15, 2022 /PRNewswire/ — (ATS International Conference) — VIDA Diagnostics, Inc. (VIDA), the leader in lung and respiratory intelligence data, is introducing a new suite of retrospective data analysis services for clinical trial sponsors in response to growing demand for precision data to optimize lung treatment trials. Announced at the 2022 American Thoracic Society ( ATS) International Conference, this suite of services empowers sponsors to leverage VIDA’s unique AI-enabled biomarker generation services and decades of validated techniques with previously generated imaging cohorts.
Full story available on Benzinga.com
[ad_2]
Source link
